A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Novartis
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
University College, London
GE Healthcare
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center